INFLUÊNCIA DA SAÚDE BUCAL SOBRE A QUALIDADE DE VIDA DE ADOLESCENTES ESCOLARES

Objetivo: Investigar o impacto da saúde bucal em relação à qualidade de vida de adolescentes escolares, associando-o às condições sociodemográficas. Métodos: Estudo de campo transversal e quantitativo desenvolvido em 2012, no município de Sumé-PB, com 184 adolescentes na faixa etária de 15 a 19 anos. Para avaliar o impacto, aplicou-se o questionário Oral Health Impact Profile (OHIP-14) aos participantes, enquanto para a obtenção dos dados referentes às condições sociodemográficas, os pais ou responsáveis responderam a um segundo questionário. Utilizou-se o teste Qui-quadrado para associar o impacto da saúde bucal sobre a qualidade de vida e as variáveis sociodemográficas pesquisadas, sendo considerados significativos com p<0,05. Resultados: Em geral, o impacto foi considerado fraco em 167 pesquisados (90,8%). “Dor física” foi a dimensão na qualidade de vida mais afetada pelas questões bucais entre aquelas que resultaram em impacto médio (22,8%; n=42). Apenas as variáveis “Situação do imóvel” e “Acomodação” associaram-se ao impacto geral (p<0,05). Os reduzidos percentuais de impacto geral forte (1,1%; n=2) relacionaram-se aos adolescentes cujas mães só estudaram até o ensino fundamental, ou às famílias que vivem com um salário mínimo ou menos (1,1%). Conclusão: Observou-se que as condições de saúde bucal apresentaram um impacto negativo fraco na qualidade de vida dos adolescentes investigados. As análises das condições sociodemográficas dos indivíduos relacionadas ao impacto geral da qualidade de vida relacionada à saúde oral associaram-se as variáveis “Situação do imóvel” e “Acomodação”.

Prevalence of chronic diseases in private healthcare sector of South Africa: A threat to public health

Purpose: To evaluate the prevalence of patients suffering from registered chronic disease list (CDL) conditions in a section of the South African private health sector from 2008 - 2012. Methods: This study was a retrospective analysis of the medicine claims database of a nationally (South African) representative Pharmacy Benefit Management (PBM) company data between 2008 and 2012. Statistical analysis was used to analyse the data. Descriptive analysis was performed to calculate the prevalence of CDL conditions for the entire population, and stratified by age and gender. However, MIXED linear modelling was used to determine changes in the average number of CDL conditions per patient, adjusted for age and gender from 2008 - 2012. Results: An increase of 0.20 in chronic diseases was observed from 2008 - 2012 in patients having any CDL condition, with an average of 1.57 (1.57 - 1.58, 95 % CI) co-morbid CDL conditions in 2008 and 1.77 (1.77 - 1.78, 95 % CI) in 2012. This increase in average number of CDL conditions per patient between 2008 and 2012 was statistically significant (p < 0.05), but with no large practical significance (d < 0.8). Conclusion: Prevalence of patients with CDL conditions along with risk of co-morbidity has been increasing with time in the private health sector of South Africa. Risk of increased co-morbidity with age and among different genders was prevalent.

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil

There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective.